Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia

Completed · Phase 2

Conditions studied: Schizophrenia, Schizoaffective Disorder

In brief

This study is to assess the safety and tolerability of a five-day titration schedule (using twice daily dosing for the first three days) to achieve the highest proposed dose of 40 mg daily. The study duration is two months.

Key facts

Study ID

NCT00139906

Run by

Solvay Pharmaceuticals

Starts

2005-08-01

Expected to finish

2006-10-01

Last updated by the study team

2015-01-16

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects who have current diagnosis of Schizophrenia or Schizoaffective disorder
• Body weight of 100-250 lbs
• Male or females
• 18-55 years of age

You may not qualify if…

• Subjects who are acutely psychotic
• Subjects with current Axis I primary psychiatric diagnosis other than schizophrenia, at significant risk of suicide

Where it is running

• Site 1 — National City, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.